```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 2809 Introduced in Senate (IS)]

<DOC>

118th CONGRESS
  1st Session
                                S. 2809

  To ensure references to opioid overdose reversal agents in certain 
 grant programs of the Department of Health and Human Services are not 
                          limited to naloxone.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 14, 2023

Mr. Cornyn (for himself and Ms. Hassan) introduced the following bill; 
     which was read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL

 
  To ensure references to opioid overdose reversal agents in certain 
 grant programs of the Department of Health and Human Services are not 
                          limited to naloxone.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Halting the Epidemic of Addiction 
and Loss Act of 2023'' or the ``HEAL Act of 2023''.

SEC. 2. REFERENCES TO OPIOID OVERDOSE REVERSAL AGENTS IN HHS GRANT 
              PROGRAMS.

    (a) In General.--In promulgating regulations or issuing guidance or 
other documents for any grant program of the Department of Health and 
Human Services that addresses opioid misuse or use disorders, the 
Secretary of Health and Human Services (referred to in this section as 
the ``Secretary'') shall ensure that any reference to an opioid 
overdose reversal agent--
            (1) shall be a reference to any drug or device approved, 
        cleared, or otherwise legally marketed under the Federal Food, 
        Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) for emergency 
        treatment of known or suspected opioid overdose; and
            (2) shall not be limited to a reference to naloxone.
    (b) Existing References.--
            (1) Update.--Not later than December 31, 2023, the 
        Secretary shall update each regulation, guidance, and other 
        document described in paragraph (2) such that any reference to 
        an opioid overdose reversal agent, including any reference to 
        naloxone, is a reference to any drug or device approved, 
        cleared, or otherwise legally marketed under the Federal Food, 
        Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) for emergency 
        treatment of known or suspected opioid overdose.
            (2) Regulations, guidance, documents described.--A 
        regulation, guidance, or other document described in this 
        paragraph is any regulation, guidance, or other document of the 
        Department of Health and Human Services that--
                    (A) was issued before the date of enactment of this 
                Act; and
                    (B) is for--
                            (i) the grant program for State and Tribal 
                        response to opioid use disorders under section 
                        1003 of the 21st Century Cures Act (42 U.S.C. 
                        290ee-3a; commonly referred to as ``State 
                        Opioid Response Grants'' and ``Tribal Opioid 
                        Response Grants''); or
                            (ii) the grant program for priority 
                        substance use disorder prevention needs of 
                        regional and national significance under 
                        section 516 of the Public Health Service Act 
                        (42 U.S.C. 290bb-22).
                                 <all>
```